🇺🇸 FDA

Intelligence · Patent portfolio

Regeneron Ireland Designated Patents

Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.

Patents
8,292
Expiring ≤24m
426

Quick answer

Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.

Page 93 of 173

  1. US 9169303

    Vault compositions for immunization

    Expires Mon Oct 22 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 9163215

    Generation of lineage-restricted progenitor cells from differentiated cells

    Expires Mon Oct 15 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 9163271

    Methods and compositions for the production of orthogonal tRNA-aminoacyl tRNA synthetase pairs

    Expires Mon Oct 15 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 9163085

    Anti-OX40 antibodies and methods of treating cancer

    Expires Mon Oct 15 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 9163248

    Targeting pseudotyped retroviral vectors

    Expires Mon Oct 15 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 9161735

    Systems, compositions, and methods for local imaging and treatment of pain

    Expires Mon Oct 15 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 9162980

    Anti-depression compounds

    Expires Mon Oct 15 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 9161969

    Protection against influenza infection by granulocyte-macrophage colony stimulating factor

    Expires Mon Oct 15 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 9156867

    Acyclic nucleoside phosphonate diesters

    Expires Mon Oct 08 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 9157916

    Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using ELISA assays

    Expires Mon Oct 08 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 9156906

    Glycopeptides and methods of making and using them

    Expires Mon Oct 08 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 9156787

    Pro-neurogenic compounds

    Expires Mon Oct 08 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 9155798

    Receptor-targeting reagents containing epidermal factor receptor-binding agents and IL-13 receptor-binding agents or IL-4 receptor-binding agents

    Expires Mon Oct 08 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 9155703

    Method and process for the production of multi-coated recognitive and releasing systems

    Expires Mon Oct 08 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 9149446

    Stabilized mutant opsin proteins

    Expires Mon Oct 01 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 9151755

    Methods for detecting Ehrlichia infection

    Expires Mon Oct 01 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 9150928

    Diagnosing and monitoring CNS malignancies using MicroRNA

    Expires Mon Oct 01 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 9150600

    Triptolide prodrugs

    Expires Mon Oct 01 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 9150581

    Nicotinic receptor compounds

    Expires Mon Oct 01 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 9149489

    Inhibitors of glycolysis useful in the treatment of brain tumors

    Expires Mon Oct 01 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 9149450

    Ischemia/reperfusion protection compositions and methods of using

    Expires Mon Oct 01 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 9149448

    Methods of treating non-alcoholic steatohepatitis (NASH) using cysteamine products

    Expires Mon Oct 01 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 9149537

    Compositions and methods for the treatment of traumatic brain injury

    Expires Mon Oct 01 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 9150598

    Masking apertures enabling automation and solution exchange in sessile bilayers

    Expires Mon Oct 01 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 9150831

    Conditionally immortalized long-term stem cells and methods of making and using such cells

    Expires Mon Oct 01 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 9145462

    Glioblastoma multiforme-reactive antibodies and methods of use thereof

    Expires Mon Sep 24 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 9144565

    Method for treating hearing loss

    Expires Mon Sep 24 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 9144605

    Recombinant rift valley fever virus encoding a dominant-negative inhibitor of DSRNA-dependent protein kinase in the NSS region

    Expires Mon Sep 24 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 9144608

    Method for stimulating retinal response using photoactive devices

    Expires Mon Sep 24 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 9139575

    Broad spectrum antiviral and antiparasitic agents

    Expires Mon Sep 17 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 9140698

    Modulating bacterial MAM polypeptides in pathogenic disease

    Expires Mon Sep 17 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 9138457

    Therapeutic modulation of ocular surface lubrication

    Expires Mon Sep 17 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 9138387

    Oral composition for removing tooth stain

    Expires Mon Sep 17 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 9138383

    Nanogel materials and methods of use thereof

    Expires Mon Sep 17 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 9139634

    Interferon-antibody fusion proteins demonstrating potent apoptotic and anti-tumor activities

    Expires Mon Sep 17 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 9138416

    Sustained-release nanoparticle compositions and methods using the same

    Expires Mon Sep 17 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 9133259

    Cartilage oligomeric matrix protein (COMP)—growth factor complexes and uses thereof

    Expires Mon Sep 10 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 9132087

    Auris formulations for treating otic diseases and conditions

    Expires Mon Sep 10 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 9132210

    Scaffolds for cell transplantation

    Expires Mon Sep 10 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 9132152

    Compositions and methods for generating induced pluripotent stem cells

    Expires Mon Sep 10 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 9126941

    Treatment of hyperproliferative disorders with diarylhydantoin compounds

    Expires Mon Sep 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 9128093

    Selective cytopheresis devices and related methods thereof

    Expires Mon Sep 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 9127050

    Multicomponent immunogenic composition for the prevention of beta-hemolytic streptococcal (BHS) disease

    Expires Mon Sep 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 9127027

    Epoxyeicosatrienoic acid analogs and methods of making and using the same

    Expires Mon Sep 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 9126978

    1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties

    Expires Mon Sep 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 9125846

    Antibodies that bind amyloid oligomers

    Expires Mon Sep 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 9125821

    Nanodrug targeting protein geranylgeranylation

    Expires Mon Sep 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 9125817

    Dual-cure dental resins and adhesives with increased cure and color-stability and low color

    Expires Mon Sep 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron Ireland Designated have?

8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron Ireland Designated patents expire?

426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.